Clinical Trials: Page 2

AstraZeneca and Merck's string of Lynparza successes ends in ovarian cancer

Results from a Phase 3 combination study in the tumor type read out negative, marking a rare miss for the pharmas' fast-growing cancer drug. 

By Jonathan Gardner • March 12, 2020

Rubius scraps lead candidate as it exits rare disease drugmaking

The once richly valued biotech cited manufacturing challenges at a contractor as a factor behind delays to its red blood cell therapy for PKU disease. 

By Jacob Bell • March 12, 2020

Gates, Wellcome hatch $125M plan to speed coronavirus treatments

Gates Foundation, Wellcome and MasterCard aim to accelerate the study of existing and new drugs for current outbreak as well as for future pathogen threats.

By Jonathan Gardner • March 10, 2020

2 newer multiple myeloma drugs fall short in bid for wider market

Phase 3 trials of Bristol Myers Squibb's Emplicti and Takeda's Ninlaro showed no benefit to adding either drug to a Revlimid-based combination in newly diagnosed patients.

By Ned Pagliarulo • March 10, 2020

Acceleron shelves drug after disappointing readout

Despite hitting the main goal of a mid-stage neuromuscular study, Acceleron isn't convinced its drug offers meaningful improvement to muscle function or quality of life.​

By Jacob Bell • March 10, 2020

Hospitals dipping into emergency stocks to combat coronavirus

Community spread of COVID-19 has hospitals bracing for a rush of patients and payers waiving fees for telemedicine consults and extra drug supplies.

By Shannon Muchmore • March 10, 2020

Tracking biopharma's response to the new coronavirus

The ongoing outbreak is a huge test for the biopharmaceutical industry and its ability to supply, develop, and test new drugs without disruption. Keep up with all of BioPharma Dive's coverage here.

By Jacob Bell • UPDATED: March 26, 2020 at noon

AstraZeneca immunotherapy combination falls short in bladder cancer trial

Results from a Phase 3 bladder cancer study combining two checkpoint inhibitors failed to show a survival benefit, raising questions about other trials.

By Jonathan Gardner • March 06, 2020

Coronavirus spread threatens spring slate of medical meetings

The American College of Cardiology and the American Academy of Allergy, Asthma and Immunology canceled their annual meetings, previously scheduled for March.

By Ned Pagliarulo • UPDATED: March 9, 2020 at 11:34 a.m.

A closer look at the Ebola drug that's become the top hope for a coronavirus treatment

Trials are underway in the U.S., China and, soon, other Asian countries to test whether remdesivir, an antiviral developed by Gilead, could have potential against SARS-CoV-2.

By Ned Pagliarulo • March 05, 2020

Takeda starts work on treatment for coronavirus illness

The plan is to take blood proteins of patients recovering from the novel virus and turn them into an immune-boosting therapy that mitigates or prevents illness in others.

By Jacob Bell • March 04, 2020

In a CRISPR first, Editas therapy used to fix genes in the body

A patient with a severe type of inherited blindness was recently treated with Editas and Allergan's CRISPR medicine, marking the first in vivo use of the gene-editing technology in adults. 

By Ned Pagliarulo • March 04, 2020

Karyopharm shares jump on positive study data for multiple myeloma drug

The cancer biotech now plans to ask the FDA to expand Xpovio's approval into earlier lines of treatment for the blood cancer.

By Ned Pagliarulo • March 02, 2020

Sangamo sees vindication in Biogen gene-editing deal

Delivering products nearly ready for clinical testing has sparked greater dealmaking interest from big pharma, Sangamo's CEO told BioPharma Dive.

By Jonathan Gardner • Feb. 28, 2020

Gilead commits to in-house development of coronavirus treatment hopeful

The biotech launched two global, Phase 3 studies of remdesivir, an experimental antiviral already being studied in trials run by Chinese researchers and the NIH.

By Ned Pagliarulo • Feb. 27, 2020

Amgen heart drug passes interim check, setting up year-end readout

Results from a large Phase 3 study of omecamtiv mecarbil, which Amgen developed with Cytokinetics, are due in the fourth quarter. 

By Ned Pagliarulo • Feb. 26, 2020

US begins first study of coronavirus treatment, testing Gilead's remdesivir

Meanwhile, another trial is getting set up in Washington to evaluate Moderna's experimental vaccine, the first vials of which were shipped to NIH Monday.

By Ned Pagliarulo • Feb. 25, 2020

In a nod toward pharma, ICER makes deal to access real-world evidence

A partnership with Aetion will give ICER more information to include in its drug reviews, but could renew debate on the usefulness of evidence collected outside of clinical study.

By Jonathan Gardner • Feb. 24, 2020

GenFit delays data readout, raising doubts about its place in NASH

Thursday's update is the second time results from a large study of the French drugmaker's main drug, called elafibranor, have been pushed back.

By Jacob Bell • Feb. 21, 2020

Teva's neuroscience drug falls short at the finish line

Austedo, a main growth driver for Teva, failed two late-stage studies that were supposed to get the drug approved as a treatment for tics in young patients with Tourette's.

By Jacob Bell • Feb. 20, 2020

Cancer concerns knock Eisai's weight loss drug from market

Eisai has agreed to remove Belviq after the FDA said a post-marketing study found a "range of cancer types" appeared to develop more frequently in patients taking the drug.

By Jacob Bell • Feb. 14, 2020

Merck builds case for Keytruda use in breast cancer

When added to chemo, Merck's immunotherapy kept a difficult-to-treat form of breast cancer from progressing, provided patients had an important biomarker.

By Jonathan Gardner • Feb. 12, 2020

Exelixis prostate cancer data could help stave off competitive threats

As Pfizer makes inroads against Cabometyx in kidney cancer, Exelixis said it will ask the FDA next year for approval in prostate disease.

By Jonathan Gardner • Feb. 11, 2020

Bayer, looking to grow pharmaceutical sales, seeds new research center

The German drugmaker is transferring a "large part" of its small molecule research unit in Berlin to contract developer and manufacturer Nuvisan, with the aim of building a new facility on Bayer's R&D campus.

By Jacob Bell • Feb. 11, 2020

In Alzheimer's, a plan to treat patients earlier doesn't work out for Lilly, Roche

Results from the DIAN-TU study chip away at the amyloid hypothesis' foundation, just as Biogen prepares to file its drug aducanumab for approval.

By Jonathan Gardner • Feb. 10, 2020